1. The first-in-class WASP activator EG-011 is active in lymphoma and multiple myeloma cell lines resistant to FDA approved compounds. (October 2022) Authors: Spriano, F.; Arribas, A.J.; Tarantelli, C.; Sartori, G.; Gaudio, E.; Driessen, C.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗